Afaaf Liberty to Anti-Retroviral Agents
This is a "connection" page, showing publications Afaaf Liberty has written about Anti-Retroviral Agents.
Connection Strength
0,870
-
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021 12 30; 385(27):2531-2543.
Score: 0,142
-
The Etiology of Pneumonia in HIV-1-infected South African Children in the Era of Antiretroviral Treatment: Findings From the Pneumonia Etiology Research for Child Health (PERCH) Study. Pediatr Infect Dis J. 2021 Sep 01; 40(9S):S69-S78.
Score: 0,138
-
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. Lancet Child Adolesc Health. 2021 09; 5(9):642-651.
Score: 0,137
-
Recovery of HIV encephalopathy in perinatally infected children on antiretroviral therapy. Dev Med Child Neurol. 2020 11; 62(11):1309-1316.
Score: 0,129
-
Behavioral Functioning and Quality of Life in South African Children Living with HIV on Antiretroviral Therapy. J Pediatr. 2020 12; 227:308-313.e2.
Score: 0,128
-
Educational delays among children living with perinatally-acquired HIV in Johannesburg, South Africa. AIDS Care. 2020 04; 32(4):438-444.
Score: 0,119
-
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet Child Adolesc Health. 2023 10; 7(10):718-727.
Score: 0,040
-
Optimizing the World Health Organization algorithm for HIV vertical transmission risk assessment by adding maternal self-reported antiretroviral therapy adherence. BMC Public Health. 2022 07 08; 22(1):1312.
Score: 0,037